Scripscan:Morepen Laboratories Ltd
cmp:10
Code:500288
Story:Morepen Laboratories Limited India manufacture APIs, Intermediates such as Loratadine, Desloratadine, Montelukast, Carvedilol, Pioglitazone, Fexofenadine and Atorvastatin and many more to export to more than 50 countries.Morepen has also integrated itself with manufacturing and marketing of finished dosage in a wide range of categories i.e. tablets, capsules and soft gels. Morepen has moved up its value chain by marketing for diagnostics and over the counter products (OTC) nationally as well as globally.Morepen also undertake contract development of Intermediates as per customer requirements.Over aggresive expansions and acquisitions killed this company some years ago.Its still struggling bigtime but future looks very uncertain to say the least.Its reeling with stiff competition and may well be an acuqisition candidate going forward.Shareholders may not have much to get as its already commanding a market cap of nearly 450crs.Retail investors with their huge fetish towards the penny priced stock fraternity would make sure that morepen always quote at par but to me this is more of a trading bet where one can look to have a position at 7-8rs only to exit at this 10-11 levels.If you are not a trader switch from this sick company to a better growth oriented candidate where capital appreciation as well as a good dividend yield backs you out.
Search This Blog(Over 800 companies covered in the blog).
Archives : Old artciles
Sunday, November 15, 2009
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
